From Genome to Pharmacome: Current Status and Future Perspectives of Multi-Omics Integration in Traditional Chinese Medicine Research
Genes · 30.05.2026 · 17 (6) · 634
DOI: 10.3390/genes17060634 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 30.05.2026. Verfasst von Tengfei Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China. Hauptthemen laut MEDLINE: Medicine, Chinese Traditional, Genomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
High-throughput sequencing and multi-omics are transforming Traditional Chinese Medicine (TCM) research from empirical descriptions toward data-driven mechanistic analyses. Unlike earlier systems pharmacology frameworks that relied primarily on static network topology and docking-based target prediction, current multi-omics approaches integrate genomic, transcriptomic, proteomic, and metabolomic data to capture dynamic, multi-scale biological responses. This review summarizes recent progress in four related areas: (i) genomic and epigenomic dissection of geo-authentic (Daodi) medicinal materials; (ii) biosynthetic pathway elucidation for major bioactive compound classes; (iii) synthetic biology platforms for heterologous production; and (iv) systems pharmacology integration for mechanism-of-action studies. We identify a central, recurrent gap: most published multi-omics analyses remain at the level of statistical association, and the biosynthetic and pharmacological pathways inferred from such data have not been validated at the causal level. To address this, we propose a tiered experimental validation framework—from biochemical target engagement through genetic perturbation to in vivo functional confirmation—and an iterative computational–experimental feedback loop. We further outline practical priorities for future work, including standardized data formats, community-endorsed metadata checklists, and coordinated DBTL pilot projects. By connecting descriptive multi-omics patterns to experimentally testable mechanistic models, TCM research can move toward precision-oriented medicine while preserving the multi-component character of traditional formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China.
- Medical School, Kunming University of Science and Technology, Kunming 650500, China.
- Department of Integrated Chinese and Western Medicine, The First People's Hospital of Yunnan Province, Kunming 650032, China.
- Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, The First People's Hospital of Yunnan Province, Kunming 650032, China.
- Department of Hematology, The First People's Hospital of Yunnan Province, Kunming 650032, China.
Zitieren
APA
Yu, T., Chen, C., Hu, P., Zou, Y., Zhang, J., Zhu, Q., & Yang, T. (2026). From Genome to Pharmacome: Current Status and Future Perspectives of Multi-Omics Integration in Traditional Chinese Medicine Research. Genes, 17(6), 634. https://doi.org/10.3390/genes17060634
Vancouver
Yu T, Chen C, Hu P, Zou Y, Zhang J, Zhu Q, et al. From Genome to Pharmacome: Current Status and Future Perspectives of Multi-Omics Integration in Traditional Chinese Medicine Research. Genes. 2026;17(6):634. doi:10.3390/genes17060634
BibTeX
@article{Yu2026,
author = {Yu, Tengfei and Chen, Changting and Hu, Peng and Zou, Yunlian and Zhang, Jinping and Zhu, Qianze and Yang, Tonghua},
title = {From Genome to Pharmacome: Current Status and Future Perspectives of Multi-Omics Integration in Traditional Chinese Medicine Research},
journal = {Genes},
year = {2026},
volume = {17},
number = {6},
pages = {634},
doi = {10.3390/genes17060634}
}
EUVIMED